Loading: 100%
SEATTLE GENETICS INC /WA logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 890 (as per Q1 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker SGENno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 174050607080
datesClosing price (adj.)
13.10.201763.00
11.10.201761.47
04.10.201758.24
27.09.201753.37
20.09.201752.84
13.09.201753.40
06.09.201751.90
30.08.201749.78
23.08.201747.65
16.08.201747.17
09.08.201748.72
02.08.201748.50
26.07.201755.02
19.07.201754.00
12.07.201753.74
05.07.201752.53
27.06.201751.39
20.06.201761.81
13.06.201762.94
06.06.201764.84
30.05.201763.32
23.05.201766.67
16.05.201763.41
09.05.201761.74
02.05.201764.18
25.04.201766.80
18.04.201766.65
11.04.201763.44
04.04.201763.19
28.03.201764.47
21.03.201761.95
14.03.201767.16
07.03.201767.12
28.02.201765.65
21.02.201765.68
14.02.201762.88
07.02.201760.79
31.01.201760.24
24.01.201758.06
17.01.201757.72
10.01.201759.01
03.01.201753.00
27.12.201652.36
19.12.201661.33
12.12.201663.82
05.12.201666.26
28.11.201666.99
21.11.201672.13
14.11.201669.56
07.11.201659.73
31.10.201651.70
24.10.201650.36
17.10.201650.14
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
63.00n/a
Market Capitalisation
in million USD
8,991n/a
Enterprise Value
in million USD
8,485n/a
Common Shares Outstanding
as per Apr 26, 2017
142,716,597n/a
Preferred Shares Outstanding
as per Apr 26, 2017
n/a
Average Basic Shares Outstanding
TTM
141,388,000n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Seattle Genetics Inc is a development-stage biotech company. It develops monoclonal antibody-based therapies. Its lead product, Adcetris, has received approval for relapsed/refractory Hodgkin\'s lymphoma and anaplastic large-cell lymphoma.
no data available
Key Financials & Ratios (all figures TTM as per Mar 31, 2017, million USD, full statements further below)
Profit & Loss
Revenues 416n/a
Gross Profit 372n/a
Operating Income -181n/a
EBITDA -162n/a
Net Profit -180n/a
Balance Sheet
Cash and Cash Equivalents 506n/a
Receivables 74n/a
Total Current Assets 656n/a
PP&E 68n/a
Total Assets 784n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 129n/a
Long-Term Debt 0n/a
Total Liabilities 181n/a
Total Equity 603n/a
Cash Flow
Depreciation & Amortisation 19n/a
Change in Working Capital -40n/a
Operating Cash Flow -143n/a
Net Change in PP&E and Intangibles -35n/a
Investing Cash Flow 59n/a
Dividends Paid 0n/a
Financing Cash Flow 40n/a
Total Change in Cash -44n/a
Free Cash Flow -237n/a
Profitability Ratios
Gross Margin 89.3%n/a
Operating Margin -43.5%n/a
Net Profit Margin -43.2%n/a
Return on Equity -29.8%n/a
Return on Assets -22.9%n/a
Per Share Figures
Basic EPS -1.27n/a
Diluted EPS n/a
Sales per Share 2.94n/a
Book Value per Share 4.27n/a
FCF per Share -1.68n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio -49.59n/a
Price to Sales Ratio 21.41n/a
Price to Book Value 14.76n/a
Price to Free Cash Flow -37.52n/a
Valuation Metrics
EV/EBITDA -52.24n/a
EV/Sales 20.39n/a
Book to Market Value 0.07n/a
Other Ratios
Current Ratio 509.1%n/a
Liabilities to Equity Ratio 29.9%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
52
107
95
211
269
287
337
418
Sales & Services Revenue
0
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
0
Cost of revenue
0
0
-3
-13
-21
-29
-37
-42
Cost of Goods & Services
0
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
0
Gross Profit
52
107
92
197
248
258
299
376
Other Operating Income
0
0
0
0
0
0
0
0
Operating Expenses
-137
-176
-236
-255
-311
-335
-420
-519
Selling, General & Administrative
-18
-29
-73
-84
-92
-104
-126
-139
Selling & Marketing
0
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
0
Research & Development
-119
-146
-163
-170
-219
-231
-295
-379
Depreciation & Amortization
0
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
0
Operating Income (Loss)
-85
-68
-144
-57
-63
-77
-121
-143
Non-Operating Income (Loss)
3
2
-8
3
0
1
0
3
Interest Expense, net
0
0
0
0
0
0
0
0
Interest Expense
0
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
0
Other Investment Income (Loss)
3
2
-8
3
0
1
0
3
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
0
0
0
Pretax Income (Loss), Adjusted
-82
-66
-152
-54
-63
-76
-120
-140
Abnormal Gains (Losses)
0
0
0
0
0
0
0
0
Acquired In-Process R&D
0
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
0
Pretax Income (Loss)
-82
-66
-152
-54
-63
-76
-120
-140
Income Tax (Expense) Benefit, net
0
0
0
0
0
0
0
0
Current Income Tax
0
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-82
-66
-152
-54
-63
-76
-120
-140
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-82
-66
-152
-54
-63
-76
-120
-140
Minority Interest
0
0
0
0
0
0
0
0
Net Income
-82
-66
-152
-54
-63
-76
-120
-140
Preferred Dividends
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-82
-66
-152
-54
-63
-76
-120
-140
Remarks
restated on Feb 29, 2012 n/a
calculated values,
restated on Feb 27, 2013 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 27, 2015 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 21, 2017 n/a
calculated values,
restated on Feb 21, 2017 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
282
331
364
374
313
650
589
Cash & Cash Equivalents
n/a
21
88
55
64
57
102
109
Short Term Investments
n/a
261
243
310
310
256
547
480
Accounts & Notes Receivable
n/a
19
55
33
30
39
53
62
Accounts Receivable, Net
n/a
19
55
33
30
39
53
62
Notes Receivable, Net
n/a
0
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
0
Inventories
n/a
0
9
38
27
43
57
68
Raw Materials
n/a
0
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
0
Other Short Term Assets
n/a
3
4
5
6
12
12
16
Prepaid Expenses
n/a
2
4
5
6
12
12
16
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
1
1
1
0
0
0
0
Total Current Assets
n/a
304
400
441
437
408
771
735
Property, Plant & Equipment, Net
n/a
12
20
25
41
46
50
63
Property, Plant & Equipment
n/a
0
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
13
0
0
0
0
63
30
Long Term Investments
n/a
0
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
0
Other Long Term Assets
n/a
0
6
6
6
5
11
11
Intangible Assets
n/a
0
0
0
0
0
0
0
Goodwill
n/a
0
0
0
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
0
6
6
6
5
11
11
Total Noncurrent Assets
n/a
26
26
31
47
51
124
104
Total Assets
n/a
330
425
471
484
459
895
838
Liabilities and owners' equity
Payables & Accruals
n/a
26 25783000
53 53048000
56 56130000
59 59348000
78 77681000
88 88031000
121 120669000
Accounts Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
29 29038000
38 38092000
44 44447000
40 39850000
48 48212000
46 46235000
28 27847000
Deferred Revenue
n/a
29 29038000
38 38092000
44 44447000
40 39850000
48 48212000
46 46235000
28 27847000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
55 54821000
91 91140000
101 100577000
99 99198000
126 125893000
134 134266000
149 148516000
Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
114 113597000
115 115227000
145 144697000
155 154515000
122 122238000
75 74918000
56 55793000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
111 110630000
110 110013000
139 138767000
149 149191000
118 117648000
71 71249000
53 53006000
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
3 2967000
5 5214000
6 5930000
5 5324000
5 4590000
4 3669000
3 2787000
Total Noncurrent Liabilities
n/a
114 113597000
115 115227000
145 144697000
155 154515000
122 122238000
75 74918000
56 55793000
Total Liabilities
n/a
168 168418000
206 206367000
245 245274000
254 253713000
248 248131000
209 209184000
204 204309000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
625 624861000
833 832829000
894 893893000
960 960498000
1,017 1017306000
1,614 1613523000
1,701 1701190000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-462 -461970000
-614 -614000000
-668 -667782000
-730 -730302000
-806 -806443000
-927 -926929000
-1,067 -1067040000
Other Equity
n/a
-1 -1373000
0 20000
0 37000
0 -11000
0 -29000
-1 -683000
0 -63000
Equity Before Minority Interest
n/a
162 161518000
219 218849000
226 226148000
230 230185000
211 210834000
686 685911000
634 634087000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
162 161518000
219 218849000
226 226148000
230 230185000
211 210834000
686 685911000
634 634087000
Total Liabilities & Equity
n/a
330 329936000
425 425216000
471 471422000
484 483898000
459 458965000
895 895095000
838 838396000
Remarks restated on n/a restated on Feb 29, 2012 n/a restated on Feb 27, 2013 n/a restated on Feb 28, 2014 n/a restated on Feb 27, 2015 n/a restated on Feb 19, 2016 n/a restated on Feb 21, 2017 n/a restated on May 1, 2017 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-82
-66
-152
-54
-63
-76
-120
-140
Net Income
0
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
0
Depreciation & Amortization
3
4
4
6
9
12
15
18
Non-Cash Items
17
19
35
29
33
40
44
56
Stock-Based Compensation
0
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
0
Change in Working Capital
-1
51
-11
30
20
-36
-71
-31
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
0
Cash from Operating Activities
-62
7
-124
11
-1
-60
-133
-97
Change in Fixed Assets & Intangibles
-5
-4
-11
-10
-22
-17
-13
-28
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
0
Net Change in Long Term Investment
-143
-8
20
-69
-2
54
-357
96
Decrease in Long Term Investment
0
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
-6
0
0
0
-5
0
Net Cash from Divestitures
0
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
0
Cash from Investing Activities
-147
-12
3
-80
-25
37
-376
68
Dividends Paid
0
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
0
0
0
0
0
0
0
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
197
7
188
36
35
16
554
35
Increase in Capital Stock
197
7
188
36
35
16
554
35
Decrease in Capital Stock
0
0
0
0
0
0
0
0
Other Financing Activities
0
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
0
Cash from Financing Activities
197
7
188
36
35
16
554
35
Net Cash Before Disc. Operations and FX
-12
3
67
-33
9
-7
45
6
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
0
Net Cash Before FX
-12
3
67
-33
9
-7
45
6
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
0
Net Changes in Cash
-12
3
67
-33
9
-7
45
6
Remarks
restated on Feb 29, 2012 n/a
calculated values,
restated on Feb 27, 2013 n/a
calculated values,
restated on Feb 28, 2014 n/a
calculated values,
restated on Feb 27, 2015 n/a
calculated values,
restated on Feb 19, 2016 n/a
calculated values,
restated on Feb 21, 2017 n/a
calculated values,
restated on Feb 21, 2017 n/a
calculated values,
restated on Feb 21, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo